Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quingestanol
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quingestanol is a synthetic progestogen primarily investigated for its contraceptive properties. It functions by activating estrone sulfatase and binding to progesterone receptors. Its contraceptive mechanism involves the inhibition of gonadotropins, leading to altered ovulation and disturbed corpus luteum function. Additionally, it modifies cervical mucus properties, inhibiting sperm penetration, and induces histological, histochemical, and ultrastructural changes in the endometrium. It has been studied as an oral contraceptive, both as a microdose monotherapy and in combination with estrogens.
- Brand names
- DemovisPilominRiglovisUnovis
- Other names
- Quingestanol acetateme-quingestanol
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on Quingestanol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quingestanol.